Introduction
The syrbactins are a family of bacterial, macrocyclic, non-ribosomal peptide natural products active against the mammalian proteasome.
1 Their α,β-unsaturated lactam functionality reacts covalently with the catalytic Thr1 residue of proteasome catalytic subunits. Given the clinical success of the proteasome inhibitors bortezomib 2 (BTZ), ixazomib, and carfilzomib 3 against cancers such as multiple myeloma and mantle cell lymphoma, 4 intense investigations into the syrbactins followed their initial discovery. 5, 6 Unlike some other proteasome inhibitors, even some used clinically, the syrbactin syringolin A is quite selective for proteasome β subunits over other protein targets, as demonstrated by affinity-based protein profiling. 7, 8, 9 Several syntheses of the natural syrbactins themselves have been reported, and significant work to prepare analogs has been pursued. [10] [11] [12] [13] We recently reported the compound TIR-199 (Chart 1), 14 the first syrbactin to demonstrate activity against tumor cell lines in animal studies. It is most potent against the chymotrypsin-like activity of the β5 constitutive proteasome subunit, which can be ascribed to structural features derived from other syrbactins including the natural product glidobactin A, which was discovered through its intrinsic activity against tumor cell lines. 15 Its key structural features include the macrolactam methyl group and the long unbranched, unfunctionalized side chain. A straight-chain alkyl urea side chain similar to that of glidobactin A was originally applied to syrbactin analogs by Kaiser. 11 Maintaining this feature in the analogs from which TIR-assays of TIR-199 showed it has low aqueous solubility without co-solvents, hampering studies of bioavailability and cellular transport. Approaches to enhance the solubility of syrbactins were therefore of high priority. Both this goal and the desire for synthetic simplification from the 10-step synthesis of TIR-199 drove the study described herein.
Chart 1. TIR-119, the approved drug bortezomib (Velcade®), and the natural product glidobactin A.
The design of the current family of syrbactins referred to informally as NAMs was based on our concise syringolin B analog synthesis 13 that can be applied to any lysine analog. Here it exploits the commercial compound β-aminoethylcysteine, or thialysine. Its sulfur was envisioned to provide a synthetic handle to enable late-stage strategies to enhance solubility. Its TIR-199-based macrodilactam can be accessed synthetically in only a few steps. The specific compounds prepared in this study are shown in Chart 2. Compounds 1 and 2 are inspired by TIR-199, including most of its structure but replacing the isolated alkene. The sulfoxide in 2 is at the same position as the alcohol of glidobactin A and could replicate its stereochemistry. 
Results

Synthesis
The synthesis of the core macrodilactam common to all of the targets prepared here is summarized in Scheme 1. The commercial aminoethylcysteine hydrochloride (7, thialysine), was converted in one pot to the ε-phosphonoacetatamide/α-Boc derivative 9 in 83% yield. Small quantities of the doubly Boc-protected and α-phosphonoacetatamide/ε-Boc amino acids were also formed, and experimental optimization was necessary to reduce their levels. Conventional carbodiimide coupling with alaninol gave 10 in 68% yield and set the stage for macrocycle formation. Dess-Martin oxidation of 10 gave an intermediate aldehyde that was neither purified nor handled unnecessarily. We have applied the Horner-Wadsworth-Emmons condensation as modified by Helquist 21 to the preparation of dozens of macrolactam analogs in the syrbactin family. This is a highly reliable process that gives superior yields in favorable circumstances.
Here, macrolactam 11 was delivered in 58% yield.
Scheme 1. Synthesis of key macrodilactam.
Stereochemical/conformational analysis of the macrolactam relied on extensive proton NMR spectra of 11. Its C2-C3 protons form an AA'BB' system and the C11-C12 protons form an ABB' system. NMR data collected on 11 and 12 (vide infra) included high field proton, COSY and NOESY spectra. They are reported in We developed a conformational model of 11 to aid in understanding its chemical and biological properties and assigned the sulfoxide configuration of 12 using this data. NOESY data were used to identify proximal transannular hydrogens, which exerted substantial constraint on the available conformations. Based on molecular modeling, there are two main low-energy conformations available to 11, with the sulfide pointing above or below the nominal plane of the ring. The macrodilactam conformation observed (Figure 1 ) has the sulfide below the plane and has NOE correlations between H-6 and both H-2a and H-12a. The similar coupling constants between H-11 and both H-12a and H-12b in 11 further support this conformation. If the sulfide was above the plane, the protons on carbon 12 would point down, which would cause the dihedral angles between H-11 and H-12a/12b to be closer to 135°. This would result in a larger coupling constant than is observed. Additionally, this structure would lack NOE correlations between the protons on carbons 3 and 12.
Compound 11 was oxidized to sulfoxide 12, obtained as a single stereoisomer (Chart 3). Least hindered approach of the reagent from the equatorial direction, as commonly observed in medium rings, would yield a beta sulfinyl group. Analysis of its 1 H NMR spectra enabled the conformation and sulfoxide configuration to be confirmed. All adjacent protons are deshielded in the sulfinyl derivative, but the relationships among hydrogens, both in terms of dipolar and scalar couplings, are very similar to 11, supporting a similar conformation. Table S1 compares the modeled dihedral angles and those implied from J couplings. Compound 12 showed additional NOE correlations between H-3b and H-12b, and H-3a and H-12a, strengthening the case for the 'sulfide below' conformation with slight inward rotation of C-3. The greatest deshielding is experienced by H-2a, which has a dihedral angle with the sulfoxide of 162°. This relationship provides the greatest downfield shift when sulfides are converted to sulfoxides. Continuing the synthesis from 11, the Boc group was removed with acid and the resulting hydrochloride salt was neutralized with a carbonate ion-exchange resin, in line with our past work. 13 The free base was then coupled with a valine active ester to provide 13. Removal of its Fmoc group and urea formation with dodecyl isocyanate provided the first target 1. Periodate oxidation yielded the sulfoxide 2 in a single stereoisomeric form, which based on spectral similarity to 12 and the precedent of its formation in the same type of reaction is assigned the beta configuration.
Scheme 2. Synthesis of TIR-199 analogs 1 and 2
The other targets required active esters 14 and 15, which were prepared conventionally from the corresponding acids. 
Biological properties
The thiasyrbactins were evaluated for their ability to inhibit each of the catalytic subunits of the constitutive and immunoproteasomes as well as for cytotoxic activity against neuroblastoma cancer cells. As 2-4 had no substantial activity in these assays, they will not be discussed.
To test the inhibitory activity of 1, 5, and 6, we performed an in vitro assay and measured the three sub-catalytic activities (i.e., the CT-L, C-L, and T-L activities) of the constitutive proteasome and the immunoproteasome (Table 3) . For control comparison, we included the While 1, 5, and 6 predominantly inhibit the CT-L and T-L activities of the constitutive proteasome, these compounds more potently and more selectively inhibit the T-L activity of the immunoproteasome, with no effect on the CT-L or C-L activities. It was initially surprising that inhibition of the T-L activity by 5 and 6 appears to stimulate the CT-L activity of the immunoproteasome ( Figure S1 ). However, such behavior has been previously observed, including in actual patient samples. 23 In contrast, BTZ inhibits the CT-L and C-L sub-catalytic activities indiscriminately, with weaker activities against the T-L activity. The immunoproteasome inhibitor ONX-0914 exhibits higher potency against the immunoproteasome CT-L activity compared to the CT-L activity of the constitutive proteasome, but also inhibited the C-L and T-L activities of both proteasome types at higher concentrations. Thus, 1, 5, and 6 more selectively target the T-L site with Ki-50 values at 0.74, 0.75, and 1.39 µM, respectively, with no effect at ≤10 µM on the CT-L and T-L activities of the immunoproteasome. In summary, all three compounds show comparable behavior with single digit micromolar inhibition of both β2 sites in addition to the β5 site of the constitutive proteasome that was expected based on the properties of TIR-199. Table 3 . In vitro effects of thiasyrbactins on sub-catalytic activities of the constitutive proteasome and the immunoproteasome.
Constitutive Proteasome Immunoproteasome
Ki-50 (µM) SD Ki-50 (µM) SD 
Molecular dynamics simulation
The actions of these compounds against the trypsin-like β2 subunits were interesting, particularly of the immunoproteasome, as selective inhibition of this sub-site has been difficult to achieve. We therefore aimed to gain structural understanding of their properties via modeling. As in our earlier work, 14 binding of a thiasyrbactin to the proteasome was evaluated using molecular mechanics/generalized Born/surface area energetic post-simulation analysis of molecular dynamics trajectories. Due to significant folding of the ring, the conformation of 5 bound to the β2 site has an even more exaggerated preference for the 'sulfide below' conformation than the free compound ( Figure 4) . Binding of syringolin A in this site was also simulated, and it binds similar to the way it binds to the β5 site of the constitutive proteasome, with the macrolactam rather flat like in its free conformation. The conformational change is quite dramatic with 5, resulting in several differences in the bound conformation compared to the natural product.
While the C5 amide is a cis amide in both, in 5 the NH lies significantly above where it is in bound SyrA. This initiates a 3-atom excursion above the area of the corresponding ring atoms in extensive non-polar protein contacts. The benzene ring of the ibuprofen is also proximal to the macrolactam that may influence the folding of this side chain against the ring. [color figure]
Discussion
The desired goals of a streamlined synthesis and enhanced solubility for syrbactin analogues were achieved in this work, though the compounds with increased solubility were not more active. Another unexpected observation was the ability of 1 and 5 to inhibit the trypsin-like β2 subunit of the immunoproteasome, whereas their parent compound, TIR-199, is a selective β5 subunit inhibitor of the constitutive proteasome. While there are several reports of selective inhibitors of the immunoproteasome trypsin-like subunit, [24] [25] [26] most are not drug-like.
Given the preference of 1 and 5 for the immunoproteasome catalytic activity that is not found in most cells, it was not very surprising that the thiasyrbactins have weak biological activity against neuroblastoma cells. Compounds 5 and 6 are more drug-like and soluble than TIR-199, though their current potency likely limits their utility to tool compounds that can elucidate the phenotypes of selectively inhibiting the β2 subunit of the proteasome. However, epoxyketone compounds are known that have selectivity somewhat like this. 27 Even though they are not very potent on their own, they show interesting synergistic activities with other proteasome inhibitors.
An important conformational change occurs in a thiasyrbactin when bound to the β2
proteasomal subunit compared to past syrbactins. The 'flipped' C10 amide and the highly folded ring results in its contacting different protein residues.
The immunoproteasome is regarded as a next-generation target for proteasome inhibitors, 28 for both autoimmune disease 29, 30 and hematologic malignancies. 31, 32 The actions of the thiasyrbactins on immune cells should prove interesting, including those associated with tumor cell growth.
Unlike bortezomib, syrbactins block the proteasome irreversibly and, importantly, do not inhibit normal proteases, 5 the latter of which being the main reason for the reported bortezomib-induced neuropathies in patients. The greater target selectivity of Syrbactins compared to bortezomib implies reduced off-target activity and more dose flexibility in animals models and patients.
Experimental Section
General. All reagents were purchased from commercial sources and were used without further purification, unless otherwise stated. Chromatographic purification of products was accomplished using flash column chromatography with silica gel 60. All melting point data were measured on a Büchi Melting Point B-545 instrument and are uncorrected. IR spectra were obtained on a Perkin Elmer Spectrum One FT-IR spectrometer or a Bruker Alpha FT-IR spectrometer using the ATR accessory and are reported in absorption frequency (cm -1 ). The specific rotation data were measured on a Rudolph Research Analytical AutoPol IV polarimeter. 33 we believe the new compounds assayed in this work have low potential for pan-assay interference and that assays to establish they do not show it were unnecessary. All tested compounds exhibited >95% purity based on clean NMR spectra without extraneous peaks. 
Synthetic methods (S)-2-(3-Dodecylureido)-3-methyl-N-((8S,11R,E)-8-methyl-
(2S)-2-(3-Dodecylureido)-3-methyl-N-((8S,11R,E)-8-methyl-1-oxido-5,10-dioxo-1-thia-4,9-
diazacyclododec-6-en-11-yl)butanamide 2. Compound 1 (12.7 mg, 22.9 μmol) was dissolved in 1.5 mL of methanol and set to stir at 0 °C. Sodium periodate (5.7 mg, 26.6 μmol) was dissolved in 0.2 mL of water and added dropwise; the reaction mixture was stirred for 24 h and concentrated in vacuo. The crude solid was purified by column chromatography (SiO 2 , methanol/dichloromethane gradient, 0:10 to 1:9) to give a white solid (7.8 mg, 60% 
N-((8S,11R,E)-8-Methyl-5,10-dioxo-1-thia-4,9-diazacyclododec-6-en-11-yl)pyrazine
N-((8S,11R,E)-8-Methyl-1-oxido-5,10-dioxo-1-thia-4,9-diazacyclododec-6-en-11-yl)pyrazine-
2-carboxamide 4. Compound 3 (6.2 mg, 17.7 μmol) was dissolved in 1 mL of methanol and set to stir at 0 °C. Sodium periodate (4.3 mg, 20.1 μmol) was dissolved in 0.1 mL of water and added drop-wise, and the reaction mixture was stirred for 24 hours and concentrated in vacuo.
The white crude solid was purified by column chromatography (SiO 2 , methanol/dichloromethane gradient, 0:10 to 1:9) to give a white solid (6.4 mg, 98% 
(S)-2-((S)-2-(4-Isobutylphenyl)propanamido)-3-methyl-N-((8S,11R,E)-8-methyl-
N-((S)-3-Methyl-1-(((8S,11R,E)-8-methyl-5,10-dioxo-1-thia-4,9-diazacyclododec-6-en-11-yl
tert-Butyl ((S)-3-((2-(2-(diethoxyphosphoryl)acetamido)ethyl)thio)-1-(((S)-1-hydroxypropan-2-
yl)amino)-1-oxopropan-2-yl)carbamate 10. L-4-Thialysine hydrochloride salt (7) (0.2965 g, 1.48 mmol) was dissolved in dioxane/water (1:1, 4 mL) and cooled to 0 °C. Sodium carbonate (0.3149 g, 2.97 mmol) was added to the mixture at 0 °C. After 30 min, phosphonoacetic acid Nhydroxysuccinimide ester (8) (0.4352 g, 1.48 mmol) was added and the mixture was stirred for 1 h at 0 °C and for 5 days at room temperature. Boc anhydride (0.6058 g, 2.78 mmol) dissolved in a minimum amount of dioxane was added drop-wise to the reaction mixture, which was stirred for 20 h at room temperature. The reaction mixture was washed with ethyl acetate (10 mL) to remove organic impurities. The aqueous phase was acidified to pH 2 using 1N hydrochloric acid, and extracted with ethyl acetate (4 × 15 mL). The combined organic extract was dried over anhydrous magnesium sulfate and concentrated to afford 9 as a colorless oil. This compound was used in the subsequent step without further purification.
The crude material 9 (0.5112 g, 1.16 mmol) was dissolved in 11 mL dry dichloromethane and Hz, 6H), 1.16 (d, J = 6.8 Hz, 3H). 13 
Biological methods
In Vitro Proteasome Activity Assay. To determine the anti-proteasome activity of the thiasyrbactins in the in vitro environment, we measured the three catalytic activities (β1, β2, β5)
of the proteasome as previously described. 13 Bortezomib (BTZ) (LC Laboratories, Woburn, MA) and the immunoproteasome inhibitor ONX-0914 (UBP Bio, Aurora, CO) were used as controls. 34 were plated overnight in RPMI media containing 10% heat-inactivated fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA, USA), supplemented with penicillin (100 U/ml) and streptomycin (100 µg/ml). Cells were cultured at 37 °C in a humidified atmosphere containing 5% CO2 and treated with 0.01, 0.1 and 1 µM proteasome inhibitor for 24 hours. Cell viability was determined using the Cell Titer 96
AQueous One Cell Proliferation Assay (Promega) reagent MTS by measuring absorbance at 490 nm using a Multi-Mode Synergy plate reader as previously described. 13 Assays were done in duplicate with triplicate wells of treatment per experiment (n=6). Data were expressed as the average cell viability relative to untreated control cells using Microsoft Excel. 
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